Tisdag 23 Juni | 19:55:12 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-11 08:30 Bokslutskommuniké 2026
2026-11-05 08:30 Kvartalsrapport 2026-Q3
2026-07-17 08:30 Kvartalsrapport 2026-Q2
2026-06-22 - Extra Bolagsstämma 2026
2026-05-26 - Årsstämma
2026-05-21 - X-dag ordinarie utdelning ORGC 0.00 SEK
2026-05-06 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-05 - Kvartalsrapport 2025-Q3
2025-08-05 - Extra Bolagsstämma 2025
2025-07-18 - Kvartalsrapport 2025-Q2
2025-05-21 - X-dag ordinarie utdelning ORGC 0.00 SEK
2025-05-20 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-07-19 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning ORGC 0.00 SEK
2024-05-15 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning ORGC 0.00 SEK
2023-05-17 - Årsstämma
2023-05-05 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ORGC 0.00 SEK
2022-05-17 - Årsstämma
2022-05-04 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2022-01-12 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-18 - X-dag ordinarie utdelning ORGC 0.00 SEK
2021-05-17 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-08 - X-dag ordinarie utdelning ORGC 0.00 SEK
2020-05-07 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-18 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning ORGC 0.00 SEK
2019-05-16 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-16 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-05-04 - X-dag ordinarie utdelning ORGC 0.00 SEK
2018-05-03 - Årsstämma
2018-02-22 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-31 - X-dag ordinarie utdelning ORGC 0.00 SEK
2017-05-30 - Årsstämma
2017-05-10 - Kvartalsrapport 2017-Q1
2017-02-22 - Bokslutskommuniké 2016
2016-12-19 - Extra Bolagsstämma 2016
2016-11-11 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-11 - X-dag ordinarie utdelning ORGC 0.00 SEK
2016-05-10 - Årsstämma
2016-05-10 - Kvartalsrapport 2016-Q1
2016-02-24 - Bokslutskommuniké 2015
2015-11-11 - Kvartalsrapport 2015-Q3
2015-08-21 - Kvartalsrapport 2015-Q2
2015-05-26 - Kvartalsrapport 2015-Q1
2015-05-05 - Årsstämma
2015-03-31 - Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorMaterial
IndustriForskning & Utveckling
OrganoClick är verksamt inom miljöteknik. Bolaget erbjuder specialiserade lösningar baserat på fiberbaserat material, där bolaget utvecklar, producerar och marknadsför funktionell fiberkemi. Produkterna används huvudsakligen inom vattenavvisande tyg och främst inom träbehandling för att beskydda mot svampförfall och brand. Bolaget grundades år 2006 och har sitt huvudkontor i Täby.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-23 15:26:00

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE ANNOUNCEMENT, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION MEASURES. PLEASE REFER TO "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

The board of directors of OrganoClick AB (publ) ("OrganoClick" or the "Company") has prepared and today publishes an information memorandum (the "Information Memorandum") in connection with the new issue of shares with preferential rights for existing shareholders of approximately SEK 39.6 million, before issue costs, which was resolved by the board of directors on 2 June 2026 and approved by the Extraordinary General Meeting on 22 June 2026 (the "Rights Issue"). The Information Memorandum is available on the Company's website, www.organoclick.com.

Summary of the Rights Issue

  • The Rights Issue comprises a maximum of 88,002,412 shares. Upon full subscription of all shares issued, the Company's share capital may increase by a maximum of SEK 880,024.147769.
  • For each existing share, four (4) subscription rights are received. Five (5) subscription rights entitle the holder to subscribe for one (1) new share in the Company.
  • The subscription price in the Rights Issue amounts to SEK 0.45 per share. The basis for the subscription price is the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during ten trading days prior to the resolution on the issue (19 May 2026 – 1 June 2026) reduced by a discount of fifteen (15) per cent.
  • Upon full subscription in the Rights Issue, the Company will receive issue proceeds of approximately SEK 39.6 million, before issue costs.
  • Subscription in the Rights Issue can take place during the period 25 June 2026 – 9 July 2026.
  • The Rights Issue is, in aggregate through subscription undertakings from the Company's larger shareholders and a majority of the board members, secured to approximately 75 per cent.

Preliminary timetable for the Rights Issue

23 June 2026Record date for receiving subscription rights and the right to participate in the Rights Issue.
25 June 2026 – 6 July 2026Trading in subscription rights.
25 June 2026 – 9 July 2026Subscription period.
Around 10 July 2026Publishing of the outcome of the Rights Issue. Contract notes are distributed.

The Information Memorandum

The Information Memorandum has been prepared in connection with the forthcoming Rights Issue and has today, on 23 June 2026, been published. The Information Memorandum, containing full terms and conditions, is available on the Company's website, www.organoclick.com.

Advisors

Advokatfirman Delphi is acting as legal advisor to the Company in connection with the Rights Issue. Eminova Fondkommission has been engaged as issuing agent in connection with the Rights Issue.

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in OrganoClick. The information in this announcement is for information purposes only and does not claim to be complete or exhaustive. No person should rely for any purpose on the information contained in this press release or its accuracy, reasonableness or completeness.

This press release does not constitute a prospectus pursuant to Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with the related delegated and implementing regulations, the "Prospectus Regulation").

This press release or the information contained in this press release may not, in whole or in part, be announced, published or distributed, directly or indirectly, in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or the United States or any other jurisdiction where such action is wholly or partly subject to legal restrictions or where such action would require additional prospectuses, registrations or other measures in addition to what is required under Swedish law. Nor may the information in this press release be forwarded, reproduced or published in a manner that contravenes such restrictions or would entail such requirements. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

No subscription rights, BTAs or new shares have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act”) or the securities laws of any state or other jurisdiction in the United States and no subscription rights, paid subscribed shares (BTAs) or new shares may be offered, subscribed, exercised, pledged, granted, sold, resold, delivered or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. In addition, the securities referred to in this press release have not been and will not be registered under applicable securities laws in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or Switzerland and, subject to certain exceptions, may not be offered or sold to or within, or for the account or benefit of, any person resident or domiciled in these countries or any other jurisdiction in which the announcement, distribution or publication would be unlawful or would require registration or any other measures. The Company has not made any offer to acquire the securities referred to in this press release to the public in any country other than Sweden.

In any EEA Member State other than Sweden (each such EEA Member State a "Relevant State"), this press release and the information contained herein is only addressed to and directed at qualified investors as defined in the Prospectus Regulation. The securities referred to in this press release are not being offered to the public in any Relevant State and are only available to qualified investors except pursuant to an exemption in the Prospectus Regulation. Persons in a Relevant State who are not qualified investors should not take any action based on this press release nor rely on it.

In the United Kingdom, this press release, and any other material relating to the securities referred to herein, is only being distributed and directed to, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ”qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/EU) incorporated into United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons falling within Article 49.2(a) to (d) (”high net worth companies, unincorporated associations etc.”) of the Order; (iii) are outside the United Kingdom; or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

Forward-looking statements
This press release contains certain forward-looking statements that are based on uncertainty because they relate to events and depend on circumstances that will occur in the future and that, by their nature, may have an impact on OrganoClick's results and financial position. Such forward-looking statements reflect OrganoClick's current expectations and are based on the information currently available. OrganoClick cannot give any assurance that such forward-looking statements will prove to be correct. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements.